Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)

NCT02307149 is registered in ClinicalTrials.gov with Viralytics as lead sponsor.

NCT NCT02307149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02307149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Lead sponsor
Viralytics
Phase
Phase 1
Overall status
Completed
Start date
May 5, 2015
Completion date
November 5, 2019
Enrollment
50 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma